Some evidence shows that the tumor mutational burden (TMB), a CD8+ T cell signature, a TGF-β immune suppressive milieu and the UBC molecular subtype can predict response to immune check-point inhibitors (ICI) as well, but a reliable predictive nomogram is still lacking. The gene discussed is TGFB1; the disease is neoplasm.